Notably, Ricco et al. showed that dynamic increases in PIVKA-II anticipated HCC onset in at-risk patients [29]; while GPC-3 may follow a different biological pattern than PIVKA-II, this hypothesis deserves further exploration before its role in risk stratification is definitively excluded. This evidence concerns the gene GPC3 and hepatocellular carcinoma.